A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis

Pharmaceuticals

on behalf of the COVID@HULP Working Group and Other Collaborators from Hospital Universitario de la Princesa¹  Pablo Zubiaur²  Gina Mejía-Abril²  Francisco Abad-Santos²  Antonio J. Carcas³  Jaime Monserrat Villatoro³  Jesús Frías³  Alberto M. Borobia³  Elena Ramírez³  Lucía Díaz García³  María Jiménez González⁴  Carmen Suarez Fernández⁵  José Ramón Arribas⁶  Guillermo Fernandez Jimenez⁷  Inés Cancio⁷  Jesús Mingorance⁸  Julio García Rodríguez⁸  José Ramón Villagrasa Ferrer⁹ 

[1] ;Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain;Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid, 28046 Madrid, Spain;Clinical Trial Unit, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain;Internal Medicine Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain;Internal Medicine Department, La Paz University Hospital-IdiPAZ, Universidad Autónoma de Madrid, 28046 Madrid, Spain;Medical Information Unit, Instituto de Investigación Sanitaria La Princesa (IP), Hospital Universitario de La Princesa, 28006 Madrid, Spain;Microbiology Department, La Paz University Hospital-IdiPAZ, 28046 Madrid, Spain;Preventive Medicine Department, Hospital Universitario de La Princesa, Faculty of Medicine, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain;

关键词: coronavirus disease 2019 (COVID-19);    severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);    hospitalisation;    mortality;    previous medication;    risk factor;   

DOI  :  10.3390/ph15010078

来源: DOAJ

【 摘 要 】

Data from several cohorts of coronavirus disease 2019 (COVID-19) suggest that the most common comorbidities for severe COVID-19 disease are the elderly, high blood pressure, and diabetes; however, it is not currently known whether the previous use of certain drugs help or hinder recovery. This study aims to explore the association of previous hospitalisation use of medication on the mortality of COVID-19 disease. A retrospective case-control from two hospitals in Madrid, Spain, included all patients aged 18 years or above hospitalised with a diagnosis of COVID-19. A Propensity Score matching (PSM) analysis was performed. Confounding variables were considered to be age, sex, and the number of comorbidities. Finally, 3712 patients were included. Of these, 687 (18.5%) patients died (cases). The 22,446 medicine trademarks used previous to admission were classified according to the ATC, obtaining 689 final drugs; all of them were included in PSM analysis. Eleven drugs displayed a reduction in mortality: azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate. Eight final drugs displayed an increase in mortality: acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol. Medication associated with survival (anticoagulants, antihistamines, azithromycin, bronchodilators, cefuroxime, colchicine, and inhaled corticosteroids) may be candidates for future clinical trials. Drugs associated with mortality show an interaction with the underlying conditions.

【 授权许可】

Unknown